Descripción de la empresa
Evaxion A/S operates as a clinical-stage biotechnology enterprise dedicated to the development of artificial intelligence-powered immunology vaccines designed to target oncological conditions. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry where innovation in vaccine technology and artificial intelligence applications defines its strategic positioning. Its operational scale is characterized by a market capitalization of $31.69M, annualized revenue of $7.53M, and an employee base consisting of 46 individuals. These valuation and revenue figures indicate that the company maintains a position as a small-cap entity with limited revenue generation relative to its peers, reflecting the typical financial profile of early-stage clinical development firms that prioritize research and development expenditures over current profit generation.
Salud financiera
The company reported revenue of $7.53M over the trailing twelve months, yet this figure was accompanied by a net income loss of $7,707,000 and an EBITDA of $-8,873,000, revealing a cost structure where expenses significantly exceed operational revenue. This substantial gap between positive revenue and negative net income demonstrates that the organization is burning cash to fund its clinical trials and research activities, which is common for clinical-stage biotech firms but indicates a current lack of profitability. Free cash flow stands at $-4,449,750, which signifies a negative financial flexibility where the company must rely on existing cash reserves or external capital raising to sustain its operations. The balance sheet presents a specific liquidity picture with $23.23M in cash against $7.50M in debt, while the debt-to-equity ratio of 44.04 suggests a leveraged position relative to equity, though the absolute debt load is manageable given the cash holdings. All three margins reflect this developmental stage: a gross margin of 100.0% indicates no cost of goods sold for revenue generated, an operating margin of -122.7% highlights high overhead costs relative to sales, and a profit margin of -102.4% underscores the deep losses on every dollar of revenue. Short-term liquidity is robust, evidenced by a current ratio of 5.85, which implies the company holds more than five times the current liabilities in liquid assets. Return on equity is -100.2% and return on assets is -28.2%, metrics that reveal that management has not yet generated positive returns on capital deployment, a standard outcome for entities in the phase 2 clinical trial stage where capital is consumed rather than returned.
Evaluación de valoración
Valuation metrics for Evaxion A/S present a distinct contrast between historical performance and future expectations, as the P/E ratio (TTM) is N/A due to negative earnings, while the forward P/E is 95.00, implying that the market prices in significant expected earnings recovery or future profitability that does not yet exist in current results. The price-to-book ratio stands at 1.86, indicating that the market values the company at a premium of roughly 86% over its book value, which suggests investors are willing to pay for the intellectual property and clinical pipeline despite current losses. Alternative valuation measures further illustrate this premium, with a price-to-sales ratio of 4.21 and an EV/EBITDA of -176.82, suggesting that traditional profitability metrics are less relevant than revenue multiple expansions driven by clinical trial milestones. Price volatility is contextually framed by a 52-week high of $12.15 and a 52-week low of $1.20, where the current share price sits significantly below the annual high, reflecting the uncertainty surrounding the company's upcoming data readouts. The beta of 0.20 indicates that the stock price exhibits low volatility relative to the broader market, moving with much less intensity than the general equity indices, which offers a different risk profile for investors seeking lower correlation assets within the biotech space.
Growth & Income
The growth profile of the company is defined by a revenue growth (YoY) of -100.0% and earnings growth (YoY) of N/A, illustrating that the business has transitioned from a revenue-generating phase to one focused entirely on capitalizing research and development costs. Since earnings are negative, they cannot grow faster or slower than revenue in a traditional sense, but rather both metrics reflect a contraction in top-line revenue as the company pivots to fund clinical trials for EVX-01 and EVX-03. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available cash and retained earnings into expanding its clinical pipeline and operational capacity rather than distributing income to shareholders. Consequently, the overall growth and income profile is entirely reliant on future clinical successes and regulatory approvals to eventually generate positive cash flows and return capital to investors, rather than providing current income through dividends or earnings growth.